Henry Schein, Inc. (HSIC) recently completed the acquisition of substantially all of the assets of Acentus, a national medical supplier specializing in the delivery of continuous glucose monitors (CGMs). Henry Schein anticipates the transaction to be neutral to 2025 non-GAAP earnings per share and accretive thereafter. Financial terms have not been disclosed.The latest acquisition expands Henry Schein’s Home Solutions business. HSIC’s Likely Stock Trend Following the NewsFollowing the announcement, shares o ...